Hims & Hers Health, Inc. (HIMS)
| Market Cap | 5.24B -22.3% |
| Revenue (ttm) | 2.21B +78.0% |
| Net Income | 133.79M +32.1% |
| EPS | 0.54 +20.8% |
| Shares Out | 227.65M |
| PE Ratio | 42.88 |
| Forward PE | 41.69 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 46,351,065 |
| Open | 22.30 |
| Previous Close | 23.48 |
| Day's Range | 21.12 - 23.62 |
| 52-Week Range | 21.12 - 72.98 |
| Beta | 2.47 |
| Analysts | Hold |
| Price Target | 41.55 (+80.5%) |
| Earnings Date | Feb 23, 2026 |
About HIMS
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $41.55, which is an increase of 80.50% from the latest price.
News
Hims & Hers removes a knock-off weight loss drug days after introducing it
Hims & Hers introduced a once-a-day weight loss pill on Thursday. Then, on Saturday, the company said it would stop offering the pill to customers.
Hims & Hers pulls copycat weight-loss pill after threats of legal action
Hims & Hers on Saturday said it would stop offering its copycat Wegovy weight-loss pill. The decision comes after Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration threatened le...
Hims & Hers to stop offering compounded semaglutide pill after FDA crackdown
Hims & Hers said in a statement on Saturday that it will stop offering access to the compounded semaglutide pill after the U.S. Food and Drug Administration said it would take action against the teleh...
Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges.
Shares of Hims & Hers Health tumbled more than 12% on Friday in after-hours trading, as the company faced increased scrutiny from federal regulators.
FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs
The FDA said “decisive steps” will be taken to restrict drugs using GLP-1 active pharmaceutical ingredients in non-approved drugs.
US signals crackdown on compounded weight-loss drugs; Hims shares tumble
The U.S. Food and Drug Administration said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs that companies such as Hims & Hers and other compounding pharmacies ha...
Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill
Hims & Hers also said it's selling a cancer-detection test that's featured in its Super Bowl ad, which plays like a commentary on the wealthy's access to better healthcare.
Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
Hims & Hers' gambit to sell a $49 compounded version of Novo Nordisk's Wegovy pill is rattling obesity shares, sparking debate about the legality of the move and threatening drugmaker returns in the b...
Novo Stock Rises, Hims & Hers Tanks. This Could Shift the Weight-Loss Copycat Battle.
Shares in the Danish drugmaker have tanked this week, dragged down by a weak sales outlook and the launch of a Wegovy knockoff.
Hims & Hers falls 8% after Novo's legal threat. Here's the latest
Online telehealth company Hims & Hers stock fell Friday after Novo Nordisk said its newly announced Wegovy pill copy was illegal and that it would take legal action. Hims is launching its pill for as ...
Novo Nordisk stock climbs out of hole on FDA chief's threat to block Hims and Hers pill
Novo Nordisk shares rallied on Friday in what's still been a painful week as the Food and Drug Administration may weigh in on the side of the Danish drugmaker in its dispute over a copycat drug.
Hims & Hers' $49 weight-loss pill jolts everyone, except its stock
Hims & Hers sent a shockwave through the pharmaceutical industry on Thursday with its announcement of a weight-loss pill with a $49-a-month introductory price. Its shares ended down anyway.
Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026
San Francisco, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice.
Hims shares plunge after FDA threatens action on 'illegal copycat drugs'
The U.S. Food and Drug Administration (FDA) will take swift action against companies that mass-market "illegal copycat drugs" by claiming they are similar to FDA-approved products, its commissioner, M...
Hims & Hers Launches New Pill That Sends Shockwaves Across Weight-Loss Drugmakers' Stocks
A new pill from Hims & Hers Health is rattling shares of leading weight-loss drugmakers.
Hims & Hers Launches Compounded Version Of Wegovy, Novo Nordisk Threatens Legal Action
Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month.
Novo Nordisk Accuses Hims & Hers of ‘Illegal Mass Compounding' Over Cheaper Wegovy Version
Hims & Hers said it would begin offering copies of Wegovy for an introductory price of $49 for the first month with a five-month plan.
Novo Nordisk CEO: Hims' $49 compounded Wegovy pill a 'waste' of money
Novo Nordisk CEO Mike Doustdar was in a meeting with investors on Thursday discussing the company's tough recent outlook when one interrupted him with shock news: U.S. telehealth firm Hims and Hers He...
Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding
Novo Nordisk said on Thursday it would take legal action against Hims & Hers after the online telehealth company said it will begin offering compounded copies of the Danish group's Wegovy pill at an i...
Hims & Hers launch of compounded $49 Wegovy pill pummels Novo Nordisk's shares
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers
Bagsværd, Denmark and Plainsboro, NJ, 5 February 2026 – Novo Nordisk today issued the following statement regarding the announcement by Hims & Hers that they will unlawfully mass-market an unapproved,...
Hims And Hers Will Undercut Wegovy Pill With $49 Copy—Novo Stock Shudders
Online pharmaceutical retailer Hims and Hers announced Thursday it will release a much cheaper, compounded version of the Wegovy weight loss pill just over half a year after Novo Nordisk caused its st...
VIEW Hims and Hers Health's compounded Wegovy pill offering fuels market jitters
Hims & Hers said it would begin offering compounded versions of Novo Nordisk's Wegovy pill at an introductory price of $49 per month.
Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
Online telehealth company Hims & Hers will launch a copy of the newly launched Wegovy pill for $49, far less than the $149 Novo sells the branded pill for. Novo Nordisk and chief rival Eli Lilly stock...
Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling pr...